U.S. generic drug maker Amneal Pharmaceuticals has entered a deal with South Korean drug maker Hanmi Pharmaceutical to acquire exclusive distribution rights for a Hanmi drug used for treating gastroesophageal reflux disease, Amneal said Monday.
The January/February 2013 Vitamins & Supplements Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Centrum, One-A-Day, NatureMade, VitaFusion, Alive, VirMax-T, MoveFree, Bioglan and Voots products.
Out of more than 200,000 entries, Procter & Gamble named "William R." of Pennsylvania winner of the ultimate sports pack as part of Wild American Flavor Sweepstakes sponsored by Prilosec OTC Wildberry.
The November/December 2012 Cough, Cold and Flu Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Mucinex, Vicks, Advil, Theraflu, Delsym, St. Joseph, Hyland's Similasan and Zicam products.
Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.
The September/October 2012 Digestive Aids Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Tums, Di-Gel, Zantac, Pepcid AC, Prilosec OTC, Prevacid 24HR, Dulcolax, Senokot and Pepto-Bismol.
Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).
Topco, a member-owned cooperative serving the food industry, recently kicked off an initiative substituting its TopCare-branded over-the-counter medicines for the equivalent prescription pharmaceutical, where appropriate, in an effort to save patient dollars and promote the TopCare brand.
A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.